School and Hospital of Stomatology, Tianjin Medical University, Tianjin, 300070, People's Republic of China.
Tianjin Stomatological Hospital, School of Medicine, Nankai University, Tianjin Key Laboratory of Oral and Maxillofacial Function Reconstruction, Tianjin, 300041, People's Republic of China.
Int J Nanomedicine. 2022 Sep 15;17:4293-4306. doi: 10.2147/IJN.S377816. eCollection 2022.
Oral squamous cell carcinoma (OSCC) is the most common type of malignant tumor in the head and neck, with a poor prognosis mainly due to recurrence and metastasis. Classical treatment modalities for OSCC like surgery and radiotherapy have difficulties in dealing with metastatic tumors, and together with chemotherapy, they have major problems related to non-specific cell death. Molecular targeted therapies offer solutions to these problems through not only potentially maximizing the anticancer efficacy but also minimizing the treatment-related toxicity. Among them, the receptor-mediated targeted delivery of anticancer therapeutics remains the most promising one. As OSCC exhibits a heterogeneous nature, selecting the appropriate receptors for targeting is the prerequisite. Hence, we reviewed the OSCC-associated receptors previously used in targeted therapy, focused on their biochemical characteristics and expression patterns, and discussed the application potential in personalized targeted therapy of OSCC. We hope that a better comprehension of this subject will help to provide the fundamental information for OSCC personalized therapeutic planning.
口腔鳞状细胞癌(OSCC)是头颈部最常见的恶性肿瘤,预后不良主要归因于复发和转移。OSCC 的经典治疗方法如手术和放疗在处理转移性肿瘤方面存在困难,与化疗一起,它们存在与非特异性细胞死亡相关的重大问题。分子靶向治疗通过不仅有可能最大限度地提高抗癌疗效,而且最大限度地减少治疗相关毒性来解决这些问题。其中,受体介导的抗癌治疗靶向递送仍然是最有前途的方法。由于 OSCC 表现出异质性,选择适当的靶受体是前提。因此,我们回顾了先前用于靶向治疗的 OSCC 相关受体,重点讨论了它们的生化特征和表达模式,并讨论了在 OSCC 个性化靶向治疗中的应用潜力。我们希望对这一主题的更好理解将有助于为 OSCC 个体化治疗计划提供基础信息。